- Conditions
- Chronic Graft-versus-host-disease
- Interventions
- Axatilimab
- Drug
- Lead sponsor
- Syndax Pharmaceuticals
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 296 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 47
- States / cities
- Birmingham, Alabama • Duarte, California • Los Angeles, California + 37 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 19,470
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma, Metastatic Oral Cavity Squamous Cell Carcinoma, Metastatic Oropharyngeal Squamous Cell Carcinoma, Pathologic Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Squamous Cell Carcinoma of Unknown Primary, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Lip and Oral Cavity Cancer AJCC v8, Stage IVA Hypopharyngeal Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8, Stage IVB Hypopharyngeal Carcinoma AJCC v8, Stage IVB Laryngeal Cancer AJCC v8, Stage IVB Lip and Oral Cavity Cancer AJCC v8, Stage IVC Hypopharyngeal Carcinoma AJCC v8, Stage IVC Laryngeal Cancer AJCC v8, Stage IVC Lip and Oral Cavity Cancer AJCC v8
- Interventions
- Carboplatin, Cemiplimab, Paclitaxel
- Drug · Biological
- Lead sponsor
- Marcelo Bonomi
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Sickle Cell Disease
- Interventions
- ICA-17043
- Drug
- Lead sponsor
- Icagen
- Industry
- Eligibility
- 16 Years to 65 Years
- Enrollment
- 297 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 42
- States / cities
- Mobile, Alabama • Little Rock, Arkansas • Davis, California + 39 more
- Conditions
- Stress Disorders, Post-Traumatic
- Interventions
- Cognitive behavioral therapy (CBT), Educational session and treatment as usual
- Behavioral
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 2
- States / cities
- New York, New York • Queens, New York
- Conditions
- ADHD, Attention Deficit Hyperactivity Disorder
- Interventions
- Atomoxetine and OROS Methylphenidate
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- Cambridge, Massachusetts
- Conditions
- Diabetic Macular Edema
- Interventions
- Experimental: Group 1 - 50mg RZ402, Experimental: Group 2 - 200mg RZ402, Experimental: Group 3 - 400mg RZ402, Placebo: Group 4 - Placebo
- Drug · Other
- Lead sponsor
- Rezolute
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 32
- States / cities
- Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 29 more
- Conditions
- Acute Renal Failure
- Interventions
- Selective cytopheretic device (SCD)
- Device
- Lead sponsor
- SeaStar Medical
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • San Diego, California • Denver, Colorado + 4 more
- Conditions
- Contraception
- Interventions
- AG200-15 (cycles 1-13), Lessina crossover to AG200-15
- Drug
- Lead sponsor
- Agile Therapeutics
- Industry
- Eligibility
- 17 Years to 40 Years · Female only
- Enrollment
- 1,504 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2012
- U.S. locations
- 80
- States / cities
- Huntsville, Alabama • Mobile, Alabama • Chandler, Arizona + 77 more
- Conditions
- FSGS
- Interventions
- DMX-200, Placebo
- Drug
- Lead sponsor
- Dimerix Bioscience Pty Ltd
- Industry
- Eligibility
- 12 Years to 80 Years
- Enrollment
- 286 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 54
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 44 more
- Conditions
- Non-Hodgkin's Lymphoma (NHL)
- Interventions
- Bendamustine hydrochloride, Ofatumumab
- Drug
- Lead sponsor
- Cephalon
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Beverly Hills, California • Stamford, Connecticut + 30 more
- Conditions
- Open-angle Glaucoma, Oular Hypertension
- Interventions
- Anecortave Acetate Sterile Suspension, 30 mg/mL, Anecortave Acetate Sterile Suspension, 60 mg/mL, Anecortave Acetate Sterile Suspension, 75 mg/mL, Anecortave Acetate Vehicle
- Drug · Other
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 201 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Advanced Solid Tumors
- Interventions
- GEN1079
- Drug
- Lead sponsor
- Genmab
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 3
- States / cities
- New Haven, Connecticut • Grand Rapids, Michigan • Lake Success, New York
- Conditions
- Advanced Malignancies
- Interventions
- MBG453, PDR001, Decitabine
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 252 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 4
- States / cities
- Baltimore, Maryland • Boston, Massachusetts • Houston, Texas + 1 more
- Conditions
- Pain, Inflammation
- Interventions
- bromfenac ophthalmic solution, placebo comparator
- Drug
- Lead sponsor
- Bausch & Lomb Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 522 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- Irvine, California
- Conditions
- Migraine
- Interventions
- Fremanezumab
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D LLC
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 499 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 32
- States / cities
- Aurora, Colorado • Colorado Springs, Colorado • Jacksonville, Florida + 27 more
- Conditions
- Diabetic Macular Edema
- Interventions
- RGX-314 Dose 1, RGX-314 Dose 2, Aflibercept (2.0 mg)
- Genetic · Biological
- Lead sponsor
- Sierra Eye Associates
- Other
- Eligibility
- 25 Years to 89 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Reno, Nevada
- Conditions
- Motion Sickness
- Interventions
- DPI-386 Nasal Gel, Placebo
- Drug
- Lead sponsor
- Repurposed Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 140 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Santa Monica, California
- Conditions
- Bilateral Nasal Polyposis
- Interventions
- Fluticasone propionate
- Drug
- Lead sponsor
- Optinose US Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 323 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 10
- States / cities
- Stockton, California • Centennial, Colorado • Louisville, Kentucky + 7 more
- Conditions
- HIV Infections
- Interventions
- Zidovudine
- Drug
- Lead sponsor
- Glaxo Wellcome
- Industry
- Eligibility
- 18 Years to 50 Years
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Research Triangle Park, North Carolina
- Conditions
- Breast Cancer, Metastatic Breast Cancer, MBC, HER2 Positive, HER2, Estrogen Receptor Positive, ER, Triple Negative
- Interventions
- Lucitanib
- Drug
- Lead sponsor
- Clovis Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 178 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 33
- States / cities
- Sedona, Arizona • Bakersfield, California • Fullerton, California + 25 more
- Conditions
- Thrombotic Thrombocytopenic Purpura (TTP)
- Interventions
- TAK-755
- Biological
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 0 Years to 70 Years
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Buffalo, New York • Durham, North Carolina + 2 more
- Conditions
- Hyperlipidemias
- Interventions
- Lapaquistat acetate and fenofibrate, Fenofibrate
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 213 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 32
- States / cities
- Huntsville, Alabama • Sierra Vista, Arizona • Beverly Hills, California + 29 more
- Conditions
- Open Angle Glaucoma, Ocular Hypertension
- Interventions
- VS101 Insert Dose A, VS101 Insert Dose B, VS101 Insert Dose C, Latanoprost 0.005% eye drops
- Drug
- Lead sponsor
- ViSci Ltd.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Bellevue, Washington
- Conditions
- Generalized Anxiety Disorder (GAD)
- Interventions
- EXOMIND (BTL-699-2) Active treatment, EXOMIND (BTL-699-2) Sham treatment
- Device
- Lead sponsor
- BTL Industries Ltd.
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 3
- States / cities
- Denver, Colorado • Chicago, Illinois • Newburgh, Indiana